TCGX, TriGemX Bio confidentially submit draft SEC registration statement for planned deal
TCGX•TriGemX Bio and TCGX Acquisition confidentially submitted a draft Form S-4 for their planned combination, which would take TriGemX Bio public on Nasdaq as TGEM. Closing is expected in the first quarter of 2027, subject to approvals.
1. Draft filing submitted
TriGemX Bio and TCGX Acquisition confidentially submitted a draft Form S-4 registration statement for their previously announced combination. The deal would take TriGemX Bio public on Nasdaq under ticker TGEM, with closing expected in the first quarter of 2027, subject to shareholder approval, the registration statement becoming effective and Nasdaq listing approval.
2. Drug trial timeline
TriGemX Bio’s migraine treatment elismetrep is in Phase 3 trials, with initial results expected in mid-2027.
